SCHEMBL10258294

SCHEMBL10258294

O=C1CNC(=O)CNC(=O)c2cccc(c2)Nc2cc(ncn2)Nc2cccc(c2)CN1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 8/20 0.49
JAK1 P23458 6/20 0.49
JAK3 P52333 6/20 0.49
CDK2 P24941 3/20 0.35
FLT3 P36888 3/20 0.35
CCNA2 P20248 2/20 0.35
CCNA1 P78396 2/20 0.35
TYK2 P29597 6/20 0.34
BMPR2 Q13873 1/20 0.34
CLK2 P49760 1/20 0.34
CLK3 P49761 1/20 0.34
GSK3B P49841 1/20 0.34
DYRK1A Q13627 1/20 0.34
PIK3CA P42336 4/20 0.33
MTOR P42345 3/20 0.33
ALK Q9UM73 3/20 0.33
PIM1 P11309 1/20 0.33
F7 P08709 4/20 0.32
F3 P13726 4/20 0.32
STK4 Q13043 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15338776 0.93 JAK2 (0.44) JAK2JAK1JAK3CDK2FLT3
SCHEMBL10257972 0.84 JAK2 (0.41) JAK2JAK1JAK3CDK2FLT3
SCHEMBL414848 0.71 JAK2 (0.37) JAK2JAK1JAK3CDK2FLT3
SCHEMBL1073309 0.71 JAK2 (0.83) JAK2JAK1JAK3TYK2ALK
SCHEMBL1075133 0.71 JAK2 (0.83) JAK2JAK1JAK3TYK2ALK
Hydrochloric Acid SCHEMBL1074541 0.70 JAK2 (0.82) JAK2JAK1JAK3TYK2ALK
SCHEMBL415813 0.68 PLK4 (0.49) JAK2JAK1JAK3CDK2FLT3
SCHEMBL415996 0.66 JAK2 (0.51) JAK2JAK1JAK3CDK2FLT3
SCHEMBL463789 0.66 BMPR2 (0.41) JAK2JAK1JAK3CDK2FLT3
SCHEMBL2519410 0.66 JAK2 (1.00) JAK2JAK1JAK3TYK2ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394955-B2 2,4 (4,6) pyrimidine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2013-03-12 US disclosed
US-8148388-B2 2,4 (4,6) pyrimidine derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 2012-04-03 US disclosed
US-20120065395-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES FREYNE EDDY JEAN EDGARD (BE) 2012-03-15 US disclosed
US-20100160310-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065395-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES NR0B1, NR1H3, NCOA3 JAK2 2835/4885JAK1 2671/4885JAK3 1897/4885
US-20100160310-A1 2,4 (4,6) PYRIMIDINE DERIVATIVES NR1H3, NR1H2, NR0B1 JAK2 2841/4885JAK1 2686/4885JAK3 2023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.